ESMO 2024: Highlights and analysis

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer

A combined PET-MRI scan could improve treatment for patients with early breast cancer